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ment. Although many prognostic factors have been
evaluated in NSCLC, no single prognostic factor has
been able to distinguish between patients in whom
relapse is likely and those in whom it is not likely with
sufficient clarity to serve as the basis for reliable thera-
peutic decisions. On the basis of recent progress in our
understanding of tumor biology, we have generated
A pproximately 50% of patients with stage I or IInon–small cell lung cancer (NSCLC) eventually
have recurrent disease after surgical resection. If it were
possible to identify the patients who are at high risk for
recurrence at the time of surgery, they could be targeted
for systemic adjuvant therapy trials, whereas those at
low risk could be spared unnecessary additional treat-
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testable hypotheses regarding the initial choice and
optimal use of combinations of prognostic factors for
NSCLC. In keeping with a widely accepted model first
proposed by Nowell,1 we assume that tumors evolve
from a near-normal state to aggressive malignancy by
the successive overgrowth of clonal cell subpopulations
that become increasingly more abnormal, owing to the
progressive accumulation of multiple genetic abnor-
malities within individual cells. These accumulated
genetic abnormalities confer various phenotypic char-
acteristics on the cells that contain them (and on their
host tumors), which include rapid growth, acquisition
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Fig 1. Schematic illustration of two strategies for reconstructing the genetic evolutionary pathways of NSCLC.
A, It is assumed that successive genetic abnormalities accumulate in individual cells and that cells representative
of early and intermediate stages persist during later stages of genetic evolution. Given that a hypothetical tumor
has gone through a sequence of changes consisting of A fi B fi C fi D, the intermediate cell forms that would
be identified when multiple measurements are performed on each cell are A, AB, ABC, and ABCD. The sequence
A fi B fi C fi D is established by the absence of cells containing B, C, or D alone, the absence of AC, AD, BC,
BD, or CD in cells with only two abnormalities, and the absence of ABD, ACD or BCD in cells with three abnor-
malities. In this hypothetical example, the acquisition of metastatic potential by cells in the primary tumor is asso-
ciated with the development of abnormality C. Patients with tumors containing cells that progressed no further
than AB would be at low risk for recurrence, whereas patients with tumors containing cells with at least abnor-
malities ABC would be at high risk for recurrence. B, If sequence A fi B fi C fi D is recapitulated in many dif-
ferent tumors of the same type, then the most advanced cells in tumors that had been characterized by multipa-
rameter analysis will exhibit only patterns A, AB, ABC, or ABCD (gray circles), and the only patients with
recurrences would be those with patterns ABC or ABCD (black circles). This hypothetical example also illus-
trates the importance of choosing measurements that are relevant to tumor progression. If there is a subset of
tumors in which the sequence of changes that drive the tumor is E fi F fi G fi H, then measurements A, B, C,
and D would be uninformative. 
A
B
of the capacity to invade locally, and acquisition of the
capacity to metastasize and survive at distant sites.
A recent review of patterns of DNA abnormalities
and oncogene expression in human solid tumors has
suggested that several sequences of genetic changes
occur preferentially in individual tumors.2 Common
sequences of genetic evolutionary changes have recently
been confirmed in human breast cancer. It was shown
that ras overexpression was a relatively late finding,
occurring in cells that already overexpressed Her-2/neu
and/or epidermal growth factor receptor in almost all
tumors studied.3 The present study was prompted by the
consideration that comparable patterns of genetic evolu-
tion might be observed in solid tumors of similar histo-
logic appearance originating at different organ sites,
particularly NSCLC. We would hypothesize that patients
who are at high risk for recurrence are those with tumors
in which abnormal cells had progressed far enough
along their respective genetic evolutionary pathways to
have acquired the capacity to metastasize. Conversely,
patients whose tumor cells had not progressed to this
extent might be at a lower risk for postoperative recurrence.
Our methodologic approach is based on the techni-
cal capability to perform multiple quantitative mea-
surements of oncogene products on each cell in a
given tumor sample by multiparameter flow cytome-
try. We have found that in most solid tumors, precur-
sor populations generally persist in the background
during and after the emergence of genetically more
advanced tumor clones.2-4 These clones are character-
ized by larger numbers of genetic abnormalities per
cell and/or higher levels of expression of individual
oncogene proteins.
If there is a specific order in which different genetic
abnormalities appear, it will quickly become apparent
when one analyzes the patterns of their co-occurrence
in individual cells. Early changes will be found unac-
companied by late abnormalities in some cells. Late
changes, however, will always be accompanied by the
presence of early genetic changes in the same cells. A
common genetic evolutionary pathway will be recog-
nizable from the patterns of increased frequencies of
occurrence of specific combinations of abnormalities
in different tumors (Fig 1).
We performed correlated quantitative measurements
of DNA content per cell, p53 protein level per cell, and
cellular levels of the Her-2/neu and ras proteins in pri-
mary tumors from 46 patients with NSCLC. In this
paper we will focus on the genetic evolutionary pat-
terns that became apparent when intertumor correla-
tions of these genetic changes leading to oncogene
product expression were analyzed.
Materials and methods
Patient population. Tumor samples were obtained from
fresh surgical specimens of primary NSCLC in patients who
underwent surgical resection at Allegheny General Hospital
between February 12, 1996, and April 23, 1998, with
informed consent, as approved by the Allegheny General
Hospital Institutional Review Board. Table I summarizes the
clinicopathologic features of these patients. Median time of
follow-up was 11.5 months, as of June 12, 1998. All 46
patients underwent pathologic staging as defined by the new
International Lung Cancer Staging outline.5
Sample preparation. Freshly obtained tumor samples
were finely scissor-minced in Hanks’ balanced salt solution
(Gibco BRL; Life Technologies, Inc, Rockville, Md), filtered
through 64 m m nylon mesh (Small Parts, Miami, Fla), and
washed once with Hanks’ balanced salt solution. Cytospin
slides (Shandon, Pittsburgh, Pa) were prepared from the cell
suspension to confirm the presence of tumor cells in each
sample, and cells were then fixed in 70% methanol for single
DNA analysis and in 0.25% paraformaldehyde followed by
70% methanol for multiparameter analysis, as previously
described.6
Immunofluorescence staining. Fluorescein-conjugated
monoclonal antibody immunospecific for p53 protein mono-
clonal Clone DO-7 was purchased from Novocastra
Laboratories Ltd (Newcastle upon Tyne, United Kingdom).
Rabbit polyclonal antibody to c-erb-B-2, purchased from
Cambridge Research Biochemicals (Cambridge, United
Kingdom), was used for indirect staining. Phycoerythrin-con-
jugated goat anti-rabbit immunoglobulin G, purchased from
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Table I. Patient characteristics
Age (y)
Mean 65
Range 36-79
Race (No.)
White 45
African American 1
Sex (No.)
Female 22
Male 24
Histopathologic type (No.)
Adenocarcinoma 19
Squamous cell carcinoma 17
Large cell carcinoma 9
Mixed adenocarcinoma/squamous cell carcinoma 1
Stage I 26
Stage II 7
Stage IIIA 11
Stage IV 2
Systemic treatment or radiation (No.)
No systemic treatment or radiation 28
Radiation therapy 10
Neoadjuvant chemotherapy and radiation 3
Neoadjuvant chemotherapy only 1
Neoadjuvant radiation therapy only 1
Unknown 3
Vector (Burlingame, Calif), was used as a secondary anti-
body. Rat monoclonal antibody to human v-H-ras, which rec-
ognizes human c-H-ras, K-ras, and N-ras, was purchased
from Oncogene Science (Cambridge, Mass). This antibody
was conjugated with Cy-5 (Amersham Life Sciences, Inc,
Pittsburgh, Pa) and used for direct staining. JC 1939, a breast
cancer cell line established in our laboratory, and for which
quantitative mean levels of p53 per cell and Her-2/neu per
cell were determined by enzyme-linked immunosorbent
assay, was used as a quantitative staining reference for p53
and Her-2/neu immunofluorescence. Lymphocytes from
healthy donors were used as low-level baseline immunofluo-
rescence staining controls and as relative reference standards
for the ras measurements.
Flow cytometry. DAPI (4,6-diamino-2-phenylindole) (for
cell DNA content measurements), FITC (fluorescein isothio-
cyanate), phycoerythrin, and Cy-5 fluorescence were mea-
sured with the use of an EPICS ELITE cytometer (Coulter,
Miami, Fla) as previously described.3
Criteria for oncogene overexpression. Flow cytometric
techniques are sufficiently sensitive to detect normal levels of
p53, which are generally in the range of 5000 to 7500 mole-
cules per cell. In the present study, intracellular levels of p53
exceeding 10,000 molecules per cell were considered abnor-
mal, and tumors in which the mean level of p53 overexpres-
sion per cell exceeded 10,000 molecules per cell were classi-
fied as p53 overexpressors. For Her-2/neu, tumors exhibiting
mean levels exceeding 150,000 molecules per cell were clas-
sified as overexpressors, and tumors exhibiting mean levels
exceeding 300,000 molecules per cell were classified as high
overexpressors. Tumors exhibiting mean levels of ras per cell
that were more than twice the lymphocyte reference (mean >
20,000 units per cell) were classified as overexpressors, and
tumors exhibiting mean levels of ras per cell that were more
than 4 times the lymphocyte reference (mean > 40,000 units
per cell) were classified as high overexpressors.
Statistical analysis. Means of 2 groups were compared
with the use of the Student t test. Associations between vari-
ables were assessed by the c 2 test or by Fisher’s exact test
when appropriate. Kaplan-Meier survival curves were com-
pared by log rank analysis. 
Results
Abnormal mean p53 expression and ploidy. Elevated
overall mean p53 levels per cell were observed in 35
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Fig 2. Multiparameter analysis of an NSCLC, illustrating the relationships among p53, Her-2/neu, ras, and ane-
uploidy in the same cells. Reference lines indicate diploid cell DNA content (vertical line) and 10,000 molecules
per cell, the upper limit for normal mean level of p53 per cell (horizontal line). A, A bivariate distribution of cell
DNA content and p53 protein content per cell. This sample contains a diploid cell population with normal levels
of p53 per cell (arrow a), a hyperdiploid cell population (arrow b) with slightly increased levels of p53 protein
per cell, and a heterogeneous aneuploid cell population with substantial overexpression of p53 protein per cell
(bracket c). B, A bivariate distribution of p53 protein content per cell and Her-2/neu protein content per cell. The
horizontal reference line for Her-2/neu is at 150,000 molecules per cell and the vertical reference line for p53 is
at 10,000 molecules per cell. This sample contains a large cell subpopulation that overexpresses p53 alone (arrow
d) but does not contain cells that overexpress Her-2/neu in the absence of p53 protein (arrow e), indicating that
p53 overexpression preceded Her-2/neu in the evolutionary sequence in this tumor. All of the cells that express
ras at high levels per cell (dots) are part of the subset of cells that also overexpress p53 and Her-2/neu (arrow f),
indicating that ras is last in the sequence.
A B
(76%) of 46 cases of NSCLC. This may be an underesti-
mate inasmuch as p53 overexpression is observed in the
presence of only about 85% to 90% of p53 mutations.
Stop codon mutations and deletions result.7,8
Among the 11 tumors that did not exhibit p53 over-
expression, 8 were diploid by flow cytometry. Five of
the diploid tumors without elevated p53 levels were
distinguished by the absence of overexpression of any
of the oncogene proteins evaluated in the present study,
suggesting that these 5 tumors followed a genetic evo-
lutionary pathway separate from that of all the other
tumors. The absence of p53 overexpression was
uncommon in aneuploid tumors, occurring in only 3 of
21 cases. Two of these aneuploid tumors showed no
other oncogene protein abnormalities as well, suggest-
ing that they might also be following a separate genet-
ic evolutionary pathway.
Abnormal mean Her-2/neu expression and ploidy.
Mean levels of Her-2/neu per cell that exceeded
150,000 molecules per cell were observed in the
diploid and/or aneuploid components of 22 (48%) of
46 tumors. The highest mean levels of Her-2/neu levels
among the aneuploid components of aneuploid tumors
by several-fold. However, Her-2/neu was rarely over-
expressed in the diploid components of aneuploid
tumors. These two findings suggest that the molecular
mechanisms that underlie Her-2/neu overexpression
may be different in diploid and in aneuploid tumors.
Furthermore, the fact that the diploid components of
aneuploid tumors frequently overexpressed p53 but not
Her-2/neu suggests that p53 overexpression preceded
Her-2/neu overexpression in many of these tumors.
Abnormal mean ras expression and ploidy.
Elevated mean levels of ras per cell were observed in
the diploid or aneuploid components of 25 (54%) of 46
tumors. High mean levels of ras per cell were observed
both in diploid tumors and in the aneuploid components
of aneuploid tumors. Like Her-2/neu, ras was rarely
The Journal of Thoracic and
Cardiovascular Surgery
Volume 118, Number 2
Shackney et al   263
Fig 3. A reconstruction of the genetic evolutionary pathways in NSCLC based on intertumor comparisons. Gray
circles represent individual tumors; black circles indicate tumors that recurred. Three pathways are identified.
Recurrences are found among the most advanced cells in pathways I and II. Pathway III was not subject to
sequence analysis, because none of the measurements performed in this study were relevant to this pathway.
overexpressed in the diploid components of aneuploid
tumors, suggesting that this abnormality often devel-
oped later than p53 overexpression in aneuploid tumors.
Abnormal mean p53 expression and mean Her-
2/neu overexpression. There was a relationship
between mean p53 level per cell and mean Her-2/neu
level per cell in the same tumor. Among 35 tumors with
elevated mean p53 levels per cell, 20 tumors also had
elevated mean Her-2/neu levels per cell (>150,000 mol-
ecules per cell); among 11 tumors in which mean p53
levels were not elevated, only 2 had mean Her-2/neu
levels per cell that exceeded 150,000 molecules per
cell. The difference was statistically significant (P =
.038 by Fisher’s exact test).
Abnormal mean p53 expression and mean ras
overexpression. There also appeared to be a relation-
ship between mean p53 level per cell and mean ras
level per cell in the same tumor. Among 35 tumors with
elevated mean p53 levels per cell, 25 tumors also had
elevated mean ras levels per cell (>20,000 molecules
per cell); among 11 tumors in which mean p53 levels
were not elevated, only 4 had mean ras levels per cell
that exceeded 20,000 molecules per cell. However, this
difference did not achieve statistical significance (P =
.07 by Fisher’s exact test).
Abnormal mean Her-2/neu expression and mean
ras overexpression. There was a strong association
between mean Her-2/neu level per cell and mean ras
level per cell in the same tumor. Among 22 tumors with
mean Her-2/neu levels exceeding 150,000 molecules
per cell, 19 tumors also had elevated mean ras levels
per cell; among 24 tumors in which mean Her-2/neu
levels were not elevated, only 10 had mean ras levels
per cell that exceeded 20,000 molecules per cell. The
difference was statistically significant (P = .002 by
Fisher’s exact test).
Intratumor cell by cell correlations. When the pat-
terns of oncogene expression were examined within
individual cells in each tumor, the most common pat-
tern observed was one in which cells that overex-
pressed p53 only were present in abundance, Her-2/neu
overexpression was commonly restricted to a subset of
cells that also overexpressed p53, and ras overexpres-
sion was observed almost exclusively in cells that also
overexpressed both Her-2/neu and p53 proteins. All of
these relationships are illustrated in the example shown
in Fig 2. In addition, in tumors that contained an aneu-
ploid component, the cells that overexpressed all three
proteins were predominantly aneuploid. In a subset of
predominantly diploid tumors that did not exhibit p53
overexpression, the majority of cells often did not
express Her-2/neu or ras either.
Genetic pathways. The foregoing relationships sug-
gest a common sequence of genetic evolutionary changes
in which p53 abnormalities develop first, followed by
Her-2/neu overexpression in a subset of p53 overexpress-
ing cells. The overexpression of ras would appear to
occur last, commonly in a subset of cells that had devel-
oped p53 and Her-2/neu abnormalities previously.
In Fig 3, individual tumors, represented by shaded
circles, are mapped to the pathway that most closely
reflects their individual patterns of oncogene expres-
sion, and each tumor is placed at a point that corre-
sponds most closely to the degree of its advancement
along that pathway. The patterns traced out by these
tumors appear to define three major genetic evolution-
ary pathways in NSCLC. The most prominent of these
(area II) is an aneuploid pathway that features p53
overexpression, and marked Her-2/neu and ras overex-
pression in its later stages. The second is a diploid path-
way (area I) that also features p53 overexpression and
marked Her-2/neu and ras overexpression in its later
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Fig 4. Disease-free survival by clinicopathologic stage
(stages I-III). There were no statistically significant stage-
related differences in disease-free survival.
Table II. Tumor recurrences in relation to stage of
disease
Stage No. of cases No of recurrences
I 26 7 (27%)
II 7 3 (43%)
III 11 4 (36%)
IV 2 0 (0%)
stages. This pathway includes a minor diploid pathway
in which p53 overexpression is not observed, but in
which Her-2/neu and ras are overexpressed. The third
distinct pathway is a diploid pathway (area III) in
which mean p53, Her-2/neu, and ras levels are all nor-
mal, as previously noted.
There were 14 tumor recurrences (30.4%) after a
median time on study of only 11.5 months. These are
shown in Fig 3 as black circles. It is apparent that recur-
rences are observed along all three of the major path-
ways and that, at least with respect to the first two path-
ways, all but 1 of the patients who had early recurrence
had primary tumors that were relatively far advanced
along their respective genetic evolutionary pathways, as
evidenced by expression of multiple oncogene products.
Two recurrent tumors classified as non-overexpressors
had mean Her-2/neu levels that were between 100,000
and 150,000 molecules per cell. Thus the threshold
accepted for elevation in the expression of this onco-
gene may have underestimated its importance for these
tumors. It is also of interest that the majority of adeno-
carcinomas and undifferentiated large cell carcinomas
were aneuploid tumors (16/29, or 55%), whereas the
majority of squamous cell carcinomas were diploid
tumors (9/17, or 53%). However, this association was
found not to be statistically significant (P = .09).
Tumor recurrence in relation to clinicopathologic
and/or genetic stage of tumor advancement was
assessed. Tumor recurrences were observed among
patients at all stages of disease and in comparable pro-
portions of patients at each stage (Table II). There were
no statistically significant differences in disease-free
survival by stage (Fig 4). However, the number of cases
in this study was relatively small, and the duration of
follow-up to date was relatively short. Most of the
recurrent tumors participating in pathways I and II
were in advanced stages of their genetic evolution (Fig
3). Among the 12 recurrences in pathways I and II, 11
overexpressed ras and 9 overexpressed both Her-2/neu
and ras. If the tumors with mean Her-2/neu levels in
the range of 100,000 to 150,000 molecules were to be
included among the Her-2/neu overexpressors, then 11
of the 12 recurrences in pathways I and II would be
classified as overexpressors of both Her-2/neu and ras.
The twelfth tumor exhibited a borderline increase in
mean p53 level per cell and normal mean Her-2/neu
and ras levels; it is conceivable that this tumor actually
may have been following pathway III. There was no
obvious correlation between clinicopathologic stage of
disease and the degree of tumor genetic evolutionary
progression (Table III). Within each genetic evolution-
ary pathway, genetically advanced stage I tumors were
found together with genetically advanced stage III
tumors; similarly, stages I, II, and III were all repre-
sented among subsets of tumors that had not advanced
very far in the genetic evolutionary sequence. The data
in Table III raise the possibility that recurrences among
patients with stage I disease may occur more common-
ly in tumors that follow pathway I, and that they may
occur later. It will be necessary to study a larger num-
ber of cases for a longer period of time to determine the
validity of this early observation.
Discussion
In this article we have presented evidence suggesting
that p53 protein overexpression, Her-2/neu overexpres-
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Table III. Tumor recurrences in relation to genetic evolutionary pathway, genetic evolutionary stage, and clinico-
pathologic stage of disease
Clinicopathologic Disease-free 
Tumor No. Pathway Degree of genetic advancement stage survival (mo)
1) 2779 I p53[N] Her-2/neu[›› ] ras[›› ] I 10.5
2) 2751 I p53[› ] Her-2/neu[N(?› )] ras[›› ] I 21.5
3) 2844 I p53[› ] Her-2/neu[› ] ras[›› ] I 11
4) 2665 I p53[› ] Her-2/neu[›› ] ras[› ] I 9
5) 2718 I p53[› ] Her-2/neu[›› ] ras[› ] II 12
6) 2855 I p53[› ] Her-2/neu[›› ] ras[›› ] I 8.5
7) 3049 I p53[› ] Her-2/neu[›› ] ras[›› ] IIIA 2.5
8) 3082 II (? III) p53[› (?N)] Her-2/neu[N] ras[N] I 4
9) 2793 II p53[› ] Her-2/neu[N(?› )] ras[›› ] IIIA 7
10) 2909 II p53[› ] Her-2/neu[› ] ras[› ] IIIA 5
11) 2824 II p53[› ] Her-2/neu[› ] ras[›› ] II 2.5
12) 2834 II p53[› ] Her-2/neu[›› ] ras[›› ] II 17.6
13) 2882 III p53[N] Her-2/neu[N] ras[N] IIIA 11
14) 2912 III p53[N] Her-2/neu[N] ras[N] I 14
sion, and ras overexpression often occurred together in
the same tumor cells in various combinations in the
majority of cases of NSCLC. Among the three protein
abnormalities studied, p53 overexpression was the only
abnormality that was commonly observed in the
absence of the other two in individual tumors and, more
specifically, within the individual diploid cell compo-
nents of individual tumors. This suggested that p53
abnormalities may have preceded the others in the
genetic evolutionary sequence that leads to aggressive
malignancy. This is consonant with published studies
that indicate that p53 mutations (which are usually
associated with p53 overexpression) often occur in
preinvasive stages of NSCLC.9-11 Ras gene mutations
have been reported to occur at very early preneoplastic
stages of development in NSCLC in some studies,12 but
not in others.13 However, overexpression of the ras pro-
tein has been found to be a late phenomenon.14 Studies
in experimental tumor systems suggest that the intro-
duction of functional wild type p53 can suppress the
transforming effects of ras overexpression in the same
cells,15 suggesting the possibility that in spontaneous
human tumors it is only when wild type p53 is neutral-
ized that ras overexpressing cells can flourish. This
premise is supported by the results of the present study.
Wild type p53 inactivation can occur within individual
cells in a number of ways and might not be accompa-
nied by overexpression of the p53 protein. Although
most missense p53 mutations result in a form of the
p53 protein that accumulates in cells, gene mutations
that result in truncation of the p53 protein can lead to
its underexpression or its total absence. Loss of wild
type p53 function can occur in the absence of p53
mutation or deletion, as a secondary or tertiary effect of
other abnormalities such as those involving MDM216,17
or p19ARF.18 Thus it is likely that some p53 abnormali-
ties went undetected in the present study, particularly in
tumors in which stigmata of wild type p53 inactivation
were present, but p53 protein levels were not elevated. 
Loss of wild type p53 function leads to a distinctive
form of genetic instability, which is often manifested
by the development of gross aneuploidy and multiple
chromosome breaks that often result in deletions,
translocations, and gene amplification.2
An association was observed in the present study
between p53 overexpression and Her-2/neu overexpres-
sion in individual tumors. Her-2/neu gene amplification
is relatively common in some human tumors, such as
breast cancer,19,20 and is often associated with levels of
Her-2/neu overexpression that are in excess of 500,000
molecules per cell.21,22 However, Her-2/neu amplifica-
tion has been reported to be a relatively uncommon
mechanism for Her-2/neu overexpression in NSCLC.23
The molecular basis for Her-2/neu overexpression in the
cases reported here remains to be elucidated.
A strong relationship between Her-2/neu overexpres-
sion and ras overexpression was observed in the pre-
sent study. Within individual cells in individual tumors,
ras overexpression was rarely observed in cells that did
not also overexpress Her-2/neu and/or p53 protein
overexpression. This suggests that ras overexpression
is a relatively late evolutionary change. Similar find-
ings have also been reported in human breast cancer.3,24
On the basis of the patterns of overexpression of p53,
Her-2/neu, and ras in individual tumors, three common
genetic evolutionary pathways for non–small cell could
be identified. The most common was an aneuploid
pathway in which the p53 fi Her-2/neu fi ras
sequence predominated. A similar pathway was found
in diploid tumors. A third pathway was identified in
which none of the proteins measured here was overex-
pressed. Early recurrences were observed in all three
pathways, and at least with respect to the first two path-
ways, recurrences were found largely among tumors
that had reached relatively advanced stages of this
genetic evolutionary schema. These genetic patterns
appear to be prognostic variables independent from
clinicopathologic stage of NSCLC.
The findings of this investigation appear promising in
identifying patients at risk for early recurrence despite
favorable clinicopathologic staging. These molecular
genetic changes may also identify patients with more
advanced clinicopathologic staging who have a more
favorable disease-free survival. These data must be
interpreted with caution, in view of the small number
of patients studied and the relatively brief duration of
follow-up. However, what may be more important than
these interim results is the method by which they were
obtained. This approach uses current understanding of
the molecular mechanisms for tumor evolution to
develop biologic risk models for recurrent disease. This
approach can provide direction for future molecular
biologic studies to further define combinations of
genetic prognostic factors associated with stage inde-
pendent virulence of NSCLC.
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Discussion
Dr Eric Vallieres (Seattle, Wash). Thank you for suggest-
ing an interesting concept on the genetic evolutionary
sequence in NSCLC. 
The field of molecular biology and genetics has grown sub-
stantially in the past decade, owing mainly to the discovery of
various genetic abnormalities, but also to the development of
different and various reproducible molecular biology tech-
niques that allow us to identify and measure these proteins.
The potential applications of these discoveries are innu-
merable and could affect the ways we prevent, diagnose,
prognosticate, or treat some of the tumors that we see.
In this retrospective study of 46 stage I to III resected
NSCLCs, you have measured the cellular contents of DNA,
p53 fi Her-2/neu fi K-ras proteins. From your observations
of the various presences of zero, one, two, or all three of the
proteins, you have postulated the following evolutionary
genetic sequence: p53 fi Her-2/neu fi K-ras. Secondarily,
you describe a possible additional prognostic tool that could
be used in treating these tumors. Please allow me a few com-
ments and questions.
Before reviewing your abstract, I had never heard of the
notion of measuring the cellular contents of these proteins. To
me, this appears to be a new technology and a new tool. Can
you compare it with other means of identifying these various
proteins? How does your technique compare with these other
techniques? How do we know that what you are measuring
are surrogates for mutations of these proteins?
Dr Landreneau. This is a prospective study that uses an
existing technology in new ways. Flow cytometry has been
used to quantitate cellular DNA content using stoichiometric
DNA-binding fluorescent dyes and to quantitate cell surface
proteins using immunofluorescent antibodies since the late
1970s. The new uses for flow cytometry in this study are as
follows: (1) It combines cell fixation techniques that cross-
link intracellular proteins (to prevent their leakage out of
cells) and then make the cell membrane permeable to per-
form valid quantitative intracellular immunofluorescent mea-
surements on each cell; (2) it focuses on the measurement of
oncogene protein products that accumulate in individual cells
during the course of tumor progression; (3) it performs mul-
tiple measurements on each cell; and (4) it quantitates as
many of these protein products as possible in absolute units
(molecules per cell) using appropriate reference cells. 
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Dr Vallieres. How does your technique compare with these
other techniques?
Dr Landreneau. Each technique has advantages and dis-
advantages. In our view, the main advantages of multipara-
meter flow cytometry (MP-FCM) in comparison with DNA-
or RNA-based techniques are as follows: (1) MP-FCM mea-
surements are performed one cell at a time on large numbers
of cells, preserving intracellular relationships among the
measured quantities and avoiding the signal averaging effects
that are inherent in methods that require the pooling of mate-
rial from large numbers of disrupted cells, and (2) they focus
on protein abnormalities that are likely to bear directly on
pathogenesis, rather than on genetic mechanisms, which may
be more relevant to etiology. In comparison with other pro-
tein-based measurements, and specifically immunohisto-
chemistry, MP-FCM appears to be more sensitive, at least
with respect to the detection of p53 protein and H-2/neu pro-
tein. Normal p53 protein levels (~5000 molecules per cell)
are usually undetectable by immunohistochemistry, whereas
MP-FCM can detect as little as 1000 to 2000 molecules per
cell. Her-2/neu protein levels are usually detected by
immunohistochemistry when they exceed 200,000 to 500,000
molecules per cell (normal levels, 20,000-80,000 molecules
per cell). MP-FCM can detect Her-2/neu reliably at levels in
the range of 50,000 molecules per cell or more. 
Dr Vallieres. How do we know that what you are measur-
ing are surrogates for mutations of these proteins?
Dr Landreneau. The relationship between cell protein
content and gene mutation is not a simple one. In the case of
p53, the key issue is abrogation of wild type p53 function,
which can occur by a variety of different mechanisms.
Mutations of the p53 gene are common, and approximately
85% of mutations are missense mutations with clear-cut p53
protein overexpression. However, abrogation of wild type p53
function can occur by mechanisms that involve neither p53
mutation nor p53 protein overexpression (eg, MDM2 or
p19ARF gene abnormalities, or p53 allelic loss). As a result, no
matter which single measurement one performs, one is likely
to miss some p53 abnormalities that result in loss of p53 func-
tion. With regard to Her-2/neu abnormalities, gene amplifica-
tion is common in breast cancer, but not in lung cancer, so
that Her-2/neu overexpression is likely to be due to indirect
effects of abnormalities in other genes that might regulate
Her-2/neu levels.
Dr Vallieres. Others have previously correlated the pres-
ence of these genetic markers with a history of tobacco expo-
sure. We know, for example, that K-ras point mutations have
been measured in a third of adenocarcinomas and in individ-
uals who have smoked or who are smoking, but fewer than
5% of adenocarcinomas are seen in nonsmokers, and similar
types of observations have been done with p53.
Do you have data concerning tobacco exposure on these 46
patients and tumors?
Dr Landreneau. All but 2 of the patients were heavy
smokers or former smokers (mean 54 pack-years, range 20-
150 pack years).
Dr Vallieres. In previous studies also, K-ras mutations
were found in up to 30% of adenocarcinomas but were not
seen in the other subtypes of NSCLC. On the other side, p53
is identified in 40% of adenocarcinomas but 70% of squa-
mous cell carcinomas. Have you analyzed the profile of these
46 tumors according to their subtypes of NSCLC? 
Dr Landreneau. MP-FCM measured intracellular ras pro-
tein content, not gene mutations, and the antibody used react-
ed with H-ras and N-ras protein as well (although most of the
ras detected in this study was likely to be K-ras). The dis-
tinction between ras protein overexpression and ras muta-
tions is an important one, inasmuch as there is not a 1:1 cor-
respondence between the two. In breast cancer, for example,
ras protein overexpression is common, but ras gene muta-
tions are not. Furthermore, K-ras mutations can occur at such
early premalignant stages of the development of solid tumors
that their prognostic usefulness might be open to some ques-
tion. In the present study, ras protein overexpression was
found to occur as a late phenomenon (commonly after the
development of p53 and Her-2/neu abnormalities). It is con-
ceivable that ras protein overexpression might reflect abnor-
malities in the intracellular functional state of ras more close-
ly than the presence or absence of mutation of the gene. In
this regard, a number of published studies in experimental
tumor systems have shown that ras overexpression is more
closely associated with the acquisition of metastatic potential
than the presence or absence of ras mutations.
Dr Vallieres. Were K-ras mutations seen in non-adenocar-
cinoma tumors?
Dr Landreneau. With regard to patterns of p53 and ras
expression by tumor subtype in the present study, the fre-
quencies of p53 overexpression were similar in adenocarci-
nomas and squamous cell carcinomas (17/19 or 89% of ade-
nocarcinomas vs 14/18 or 78% of squamous cell cancers) and
a little lower in large cell undifferentiated tumors (6/9 or
67%). The frequencies of ras overexpression were also simi-
lar in adenocarcinomas and squamous cell carcinomas (14/19
or 74% of adenocarcinomas vs 11/18 or 61% of squamous
cell cancers) and somewhat lower in large cell undifferentiat-
ed tumors (4/9 or 44%). We should not try to read too much
into these frequency data, because the number of patients is
still relatively small.
Dr Vallieres. The next comment is that we know that in
small cell lung cancers p53 abnormalities will be seen in 80%
of these tumors, but K-ras and Her-2/neu abnormalities are
infrequent. Can you comment on that?
Dr Landreneau. Although we did not examine small cell
lung tumors in this study, our findings in NSCLC appear to
be different from those reported in the literature for small cell
lung cancer, in which Her-2/neu and ras abnormalities are
uncommon. We suspect that this may be due to the loss of Rb
protein in small cell lung cancer. The mitogenic signaling
pathway ordinarily proceeds from the activation of mem-
brane signaling receptors like Her-2/neu though activation of
ras, raf, MEK, and MAPK, the induction of cyclin D1, cyclin
D/cdk4-mediated phosphorylation of Rb, and the release of
free E2F1, which leads to a round of DNA synthesis and cell
division. In tumors in which Rb protein is intact (which
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includes the majority of NSCLCs), a strategy of chronic
mitogenic stimulation might account for many known obser-
vations (such as epidermal growth factor receptor or Her-
2/neu overexpression, ras overexpression, cyclin D1 overex-
pression, and/or loss of the cyclin D1/cdk4 inhibitor, p16).
However, one might expect that when Rb protein is lost or
inactivated (as in nearly all small cell lung cancers), the link-
age between early steps in the mitogenic signaling pathway
and E2F1-mediated DNA synthesis would be disrupted, ren-
dering any abnormalities in these early steps irrelevant to cell
cycle progression. Thus we would speculate that in Rb-nega-
tive small cell lung cancer, Her-2/neu overexpression and/or
ras abnormalities would offer no proliferative advantage, and
they would not be favored by evolutionary selection.
Dr Vallieres. What percentage of the tumors had both K-
ras and p53?
Dr Landreneau. On the basis of the criteria that we used
for distinguishing high levels of expression of p53 and ras
from low levels of expression, 25 (54%) of 46 tumors con-
tained cells that overexpressed both in the same cells.
Dr Vallieres. This probably reflects a difference in the
technique of measuring, because previously both proteins
were measured in only about 10% of these tumors.
This evolutionary concept is new and interesting. Whether
the sequence is real or whether the simultaneous presence of
these three or even more abnormalities only reflects a direct
effect of carcinogen exposure without sequencing needs to be
clarified. The identification of these three proteins and resect-
ed tumors appears to identify bad plain tumors and could
potentially serve as an additional prognostic tool to help guide
therapy. Identification of these proteins on pre-resected sam-
pling could potentially lead to interesting induction strategies
and therapies. However, as you stated yourself, this study is
early, it is small, and the follow-up remains relatively short.
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